tradingkey.logo

OptimizeRx Corp

OPRX
15.920USD
+0.030+0.19%
Market hours ETQuotes delayed by 15 min
295.99MMarket Cap
8705.64P/E TTM

OptimizeRx Corp

15.920
+0.030+0.19%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of OptimizeRx Corp

Currency: USD Updated: 2025-11-11

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

OptimizeRx Corp's Score

Industry at a Glance

Industry Ranking
69 / 485
Overall Ranking
145 / 4608
Industry
Software & IT Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 7 analysts
Buy
Current Rating
24.833
Target Price
+50.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

OptimizeRx Corp Highlights

StrengthsRisks
OptimizeRx Corporation is a digital health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers diverse tech-enabled marketing solutions through its artificial intelligence (AI)-generated Dynamic Audience and Activation Platform (DAAP), which enables customers to execute traditional marketing campaigns on its digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. Its principal solutions include Audience Development, Audience Activation and Media Execution and Financial Messaging. Its Financial Messaging solutions provide prescribers visibility to branded copay offers directly within their electronic health record (EHR) systems and/or electronic prescribing (ERx) platforms.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 47.52% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 92.13M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 92.13M.
Overvalued
The company’s latest PE is 3678.24, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 13.52M shares, decreasing 29.35% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 790.64K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.89.

Financial Health

Currency: USD Updated: 2025-11-11

The company's current financial score is 9.13, which is higher than the Software & IT Services industry's average of 7.26. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 26.07M, representing a year-over-year increase of 22.33%, while its net profit experienced a year-over-year increase of 108.54%.

Score

Industry at a Glance

Previous score
9.13
Change
0

Financials

8.53

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

9.50

Shareholder Returns

7.61

OptimizeRx Corp's Company Valuation

Currency: USD Updated: 2025-11-11

The company’s current valuation score is 7.11, which is lower than the Software & IT Services industry's average of 7.30. Its current P/E ratio is 3678.24, which is 3.90% below the recent high of 3821.76 and 101.10% above the recent low of -40.41.

Score

Industry at a Glance

Previous score
7.11
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 69/485
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-11

The company’s current earnings forecast score is 8.29, which is higher than the Software & IT Services industry's average of 7.59. The average price target for OptimizeRx Corp is 24.00, with a high of 32.00 and a low of 20.00.

Score

Industry at a Glance

Previous score
8.29
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts
Buy
Current Rating
24.833
Target Price
+56.28%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

104
Total
7
Median
14
Average
Company name
Ratings
Analysts
OptimizeRx Corp
OPRX
7
Meta Platforms Inc
META
68
Alphabet Inc
GOOGL
66
Uber Technologies Inc
UBER
56
Netflix Inc
NFLX
51
Shopify Inc
SHOP
50
1
2
3
...
21

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-11

The company’s current price momentum score is 6.73, which is lower than the Software & IT Services industry's average of 6.96. Sideways: Currently, the stock price is trading between the resistance level at 20.49 and the support level at 13.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.94
Change
-0.21

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-1.116
Neutral
RSI(14)
37.219
Neutral
STOCH(KDJ)(9,3,3)
19.068
Neutral
ATR(14)
1.570
High Vlolatility
CCI(14)
-146.078
Sell
Williams %R
85.484
Oversold
TRIX(12,20)
-0.164
Sell
StochRSI(14)
18.501
Oversold
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
17.230
Sell
MA10
18.503
Sell
MA20
19.345
Sell
MA50
18.818
Sell
MA100
16.653
Sell
MA200
12.736
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-11

The company’s current institutional recognition score is 7.00, which is higher than the Software & IT Services industry's average of 5.80. The latest institutional shareholding proportion is 72.70%, representing a quarter-over-quarter decrease of 10.07%. The largest institutional shareholder is The Vanguard, holding a total of 1.06M shares, representing 5.68% of shares outstanding, with 12.07% increase in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Whetstone Capital Advisors, LLC
1.51M
--
Weintraub (Michael)
1.38M
--
BlackRock Institutional Trust Company, N.A.
1.09M
-6.23%
The Vanguard Group, Inc.
Star Investors
920.88K
-0.10%
Royce Investment Partners
Star Investors
790.64K
-20.48%
William Blair & Company, L.L.C. (Research)
628.93K
-0.33%
Rice Hall James & Associates, LLC
607.56K
+5.45%
Febbo (William J)
530.85K
-13.54%
Parkman Healthcare Partners LLC
507.42K
+6.83%
Kennedy Capital Management LLC
472.47K
-1.24%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-11

The company’s current risk assessment score is 3.58, which is lower than the Software & IT Services industry's average of 4.86. The company's beta value is 1.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
3.58
Change
0
Beta vs S&P 500 index
1.09
VaR
+6.23%
240-Day Maximum Drawdown
+37.65%
240-Day Volatility
+96.53%

Return

Best Daily Return
60 days
+10.67%
120 days
+34.74%
5 years
+51.69%
Worst Daily Return
60 days
-17.37%
120 days
-17.37%
5 years
-33.98%
Sharpe Ratio
60 days
+0.08
120 days
+1.10
5 years
+0.08

Risk Assessment

Maximum Drawdown
240 days
+37.65%
3 years
+80.26%
5 years
+96.10%
Return-to-Drawdown Ratio
240 days
+6.42
3 years
-0.00
5 years
-0.14
Skewness
240 days
+3.08
3 years
+1.76
5 years
+1.15

Volatility

Realised Volatility
240 days
+96.53%
5 years
+82.06%
Standardised True Range
240 days
+5.45%
5 years
+9.49%
Downside Risk-Adjusted Return
120 days
+212.97%
240 days
+212.97%
Maximum Daily Upside Volatility
60 days
+46.05%
Maximum Daily Downside Volatility
60 days
+55.12%

Liquidity

Average Turnover Rate
60 days
+1.78%
120 days
+2.52%
5 years
--
Turnover Deviation
20 days
+89.46%
60 days
+34.02%
120 days
+89.13%

Peer Comparison

Software & IT Services
OptimizeRx Corp
OptimizeRx Corp
OPRX
7.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
QXO Inc
QXO Inc
QXO
8.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amdocs Ltd
Amdocs Ltd
DOX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Akamai Technologies Inc
Akamai Technologies Inc
AKAM
8.55 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ePlus inc
ePlus inc
PLUS
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
CACI International Inc
CACI International Inc
CACI
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI